Hello Avatar! Welcome to the BowtiedBiotech podcast, where science meets business! If you're fascinated by breakthrough biotech, bold innovations, and the business behind the science, you're in the right place. Each week, we dive into the world of biotech with fresh insights, sharp analysis, and the stories that are shaping the future of health. Whether you’re an industry insider, an investor, or just biotech-curious, we’ve got something for you.
We are now publishing 7x per week according to the following cadence:
Mondays: Stocks
Tuesdays: Biotech
Wednesdays: Podcast
Thursdays: Markets
Fridays: News
Saturdays: Podcast
Sundays: Strategy
We are also publishing unique content on X - be sure to follow up if you are not already @BowTiedBiotech. And to check-out the archive of our work on X you can find it on our website at: BowtiedBiotech.subtack.com/x-articles.
SUBSCRIBE TO PODCAST HERE:
Please help spread the work by subscribing and hitting the share button if you are enjoying content!
This week on BowTiedBiotech, we break down a packed slate of clinical, regulatory, financing, and M&A developments across the sector. Sanofi walks away from a once-promising eczema program, Scribe tests investor appetite with the first gene-editing IPO in more than two years, GSK gets an early regulatory payoff from its $10.6 billion Nuvalent acquisition, and Summit faces a high-stakes FDA decision with less than a year of cash remaining. We also cover Lilly’s $3.8 billion psychedelic bet, Arrowhead’s strong Phase 3 data, the risks of proposed tariffs on imported generics, Amgen’s fight to keep Tavneos on the market, Repligen’s move deeper into the cell-therapy supply chain, and an FDA peptide vote that may signal a lower evidentiary bar. The common thread is simple: behind every bullish headline sits a harder question about safety, durability, financing, valuation, or regulatory risk.
📣🎙️ TODAY’S PODCAST:
[02:51] Sanofi’s billion-dollar failure
[05:37] GSK’s $10.6B approval gamble
[07:51] Scribe reopens gene editing
[10:26] Summit enters the binary trap
[13:09] Repligen builds biotech infrastructure
[15:03] Lilly bets on psychedelics
[17:03] Arrowhead delivers hard data
[19:17] Generic tariffs threaten shortages
[20:48] Amgen defends Tavneos
[22:32] FDA peptides lower the bar
Thanks for reading BowTiedBiotech! Please help us grow our audience - sharing is caring!
CONCLUSION
We hope you are enjoying our first leap into the podcast world! Instead of waiting until everything is perfect, we’re diving in and will continue improving as we go. Feel free to send us your suggestions, feedback, or constructive criticism—we’d love to hear from you!
As a reminder, if looking to go deeper into the topics we cover check out our website BowTiedBiotech.com, or DM us on twitter, or email us: bowtiedbiotech@gmail.com
ABOUT BOWTIEDBIOTECH
As a reminder, the purpose of the BowTiedBiotech substack is two-fold. Primarily, we aim to provide our scientist audience the tools to build a biotech company and ultimately translate their ideas into medicines for patients. Secondarily, biotech investors may find this substack useful as we will be providing weekly market updates of the public AND private markets as well as heavily leveraging current financing events as teaching examples.
DISCLAIMER
None of this is to be deemed legal or financial advice of any kind. All updates are sourced from publicly available disclosures. Insights are *opinions* written by an anonymous cartoon/scientist/investor.
TOP BOWTIEDBIOTECH NEWSLETTERS
